Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.

Sinisalo M, Silvennoinen R, Wirta O.

Am J Hematol. 2012 Jun;87(6):640. doi: 10.1002/ajh.23189. Epub 2012 Mar 31.

2.

Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.

Ward F, Dunne O, Crotty TB, Fennelly D, Watson A, Holian J.

Ir Med J. 2012 May;105(5):148-9.

PMID:
22803494
3.

[Improved prognosis in light chain nephropathy due to multiple myeloma].

Juul JS, Larsen T, Marcussen N, Pedersen EB.

Ugeskr Laeger. 2012 Apr 23;174(17):1159-60. Danish.

PMID:
22533933
4.

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M.

Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035.

5.

Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.

Hasegawa M, Kondo F, Yamamoto K, Murakami K, Tomita M, Nabeshima K, Nakai S, Kato M, Ohashi A, Arai J, Hiki Y, Ishii J, Emi N, Sugiyama S, Yuzawa Y.

Ther Apher Dial. 2010 Oct;14(5):451-6. doi: 10.1111/j.1744-9987.2010.00863.x.

PMID:
21175542
6.

Renal improvement in myeloma with bortezomib plus plasma exchange.

Burnette BL, Leung N, Rajkumar SV.

N Engl J Med. 2011 Jun 16;364(24):2365-6. doi: 10.1056/NEJMc1101834. No abstract available.

7.

Renal improvement in myeloma with plasma exchange.

Hutchison C, Bridoux F, Fermand JP.

N Engl J Med. 2011 Sep 15;365(11):1061; author reply 1062. doi: 10.1056/NEJMc1108282#SA1. No abstract available.

PMID:
21916654
8.

The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.

Cockwell P, Cook M.

Adv Chronic Kidney Dis. 2012 Sep;19(5):324-32. doi: 10.1053/j.ackd.2012.06.003. Review.

PMID:
22920643
9.

Renal improvement in myeloma with plasma exchange.

Haspel RL, Cserti-Gazdewich C, Dzik WH.

N Engl J Med. 2011 Sep 15;365(11):1061-2; author reply 1062. doi: 10.1056/NEJMc1108282#SA2. No abstract available.

PMID:
21916653
10.

[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].

de Alarcón Jiménez RM, Roca Meroño S, Alvarez Fernández GM, García Hernández MA, Navarro Parreño MJ, Jimeno Griñó C, Zarco Pedrinaci E, Molina Núñez M.

Nefrologia. 2011;31(2):238-40. doi: 10.3265/Nefrologia.pre2010.Aug.10496. Review. Spanish. No abstract available.

11.

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D.

Nephrol Dial Transplant. 2012 Oct;27(10):3823-8. doi: 10.1093/ndt/gfr773. Epub 2012 Jan 23.

PMID:
22273664
12.

Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.

Borrego-Hinojosa J, Pérez-del Barrio MP, Biechy-Baldan Mdel M, Merino-García E, Sánchez-Perales MC, García-Cortés MJ, Ocaña-Pérez E, Gutiérrez-Rivas P, Liébana-Cañada A.

Nefrologia. 2013;33(4):515-23. doi: 10.3265/Nefrologia.pre2013.Feb.11932. English, Spanish.

13.

Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.

Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.

Transplant Proc. 2009 Dec;41(10):4407-10. doi: 10.1016/j.transproceed.2009.10.005.

PMID:
20005409
14.

Management options for cast nephropathy in multiple myeloma.

Cockwell P, Hutchison CA.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):550-5. doi: 10.1097/MNH.0b013e32833ef72c. Review.

PMID:
20827195
15.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
16.

Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.

Qayum A, Aleem A, Al Diab AR, Niaz F, Al Momen AK.

Saudi J Kidney Dis Transpl. 2010 Jan;21(1):63-8.

17.

Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.

Krieter DH, Devine E, Wanner C, Storr M, Krause B, Lemke HD.

Artif Organs. 2014 Oct;38(10):888-93. doi: 10.1111/aor.12248. Epub 2014 Jan 7.

PMID:
24392952
18.

[Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].

Vokurka S.

Klin Onkol. 2010;23(4):242-4. Review. Czech.

PMID:
20806822
19.

Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.

Rodríguez-Martín M, Sáez-Rodríguez M, García-Bustínduy M, Martín-Herrera A, Noda-Cabrera A.

Dermatol Online J. 2008 Nov 15;14(11):14.

PMID:
19094852
20.

Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.

Timurağaoğlu A, Ozkaynak C, Tuzuner S, Bostan F, Undar L.

Acta Haematol. 2007;118(4):203-4. Epub 2007 Nov 9. No abstract available.

PMID:
17992010

Supplemental Content

Support Center